<DOC>
	<DOCNO>NCT02459795</DOCNO>
	<brief_summary>The purpose study compare safety efficacy Perrigo 's drug compare FDA approve drug treatment actinic keratosis .</brief_summary>
	<brief_title>To Compare Safety Efficacy Perrigo 's Drug Compared FDA Approved Drug Treatment Actinic Keratosis</brief_title>
	<detailed_description />
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis , Actinic</mesh_term>
	<criteria>1 . IRB approve write inform consent/assent study . 2 . Healthy male female , least 18 year age . 3 . General good health free clinically significant disease , Actinic Keratosis 4 . Clinical diagnosis Actinic Keratosis , define 4 8 clinically typical , visible discrete , nonhyperkeratotic , nonhypertrophic , Actinic Keratosis lesion within contiguous 25cm2 treatment area . 5 . Willing refrain use lotion , sunscreen , moisturizers , cleanser , cream treatment area treatment period . NonMedicated moisturizers , emollient , humectant , sunscreen similar product use routinely prior start trial subject , may use treatment period . 6 . Willing refrain use type bandage occlusive dressing treatment area apply gel open skin wound , infection exfoliative dermatitis . 7 . Willing able understand comply requirement study , apply study medication instruct , refrain use topical Actinic Keratosis medication 57 day ( 8 week ) study period , return require study visit , comply therapy prohibition , able complete study . 8 . Females childbearing potential ( exclude woman surgically sterilize postmenopausal least 2 year ) , addition negative urine pregnancy test Visit 1/Day 1 ( Baseline ) , must willing use acceptable form birth control study . 1 . Pregnant , nursing , plan pregnancy within study period . 2 . Immunocompromised HIV positive immunesystem disorder include autoimmune disease . 3 . Active herpes infection within 14 day prior Visit1/Day 1 ( Baseline ) ( i.e. , include presence herpes labialis ) . 4 . Any evidence systemic cancer , squamous cell carcinoma , basal cell carcinoma , cancer treatment area . 5 . Presence incompletely heal wound within treatment area within 5 cm treatment area . 6 . Presence confound skin condition treatment area may make bad treatment Ingenol Mebutate gel ( e.g. , psoriasis , atopic dermatitis , eczema ) . 7 . Subjects use tan salon and/or tan booth sunbathe excessive prolonged exposure sun 7 day prior Visit 1/Day 1 ( Baseline ) plan throughout study . 8 . Subjects plan use artificial tanner within 5 cm select treatment area throughout study . 9 . Use NSAIDs within 7 day Visit 1/Day 1 ( Baseline ) initiation study . *Subjects may use Tylenol ( Acetaminophen ) pain relief , need , throughout study . Subjects may use low dose aspirin ( 81mg ) cardiac prophylaxis throughout study . 10 . Subjects cosmetic therapeutic procedure follow within 2 cm select treatment area within 2 week ( 14 day ) Visit 1/Day 1 ( Baseline ) within 10 cm select treatment area plan anytime study . Cryodestruction/ cryotherapy/liquid nitrogen Surgical excision Curettage Dermabrasion Medium great depth chemical peel Laser resurface 11 . Subjects schedule elective surgery within 1 month ( 30 day ) study period . 12 . Use within 1 month ( 30 day ) prior Visit 1/Day 1 ( Baseline ) plan use study : Immunomodulators ( i.e . azathioprine ) Immunosuppressive therapy ( i.e. , cyclosporine , prednisone , methotrexate , alefacept , infliximab ) Interferon Interferon inducer Systemic corticosteroid ( oral injectable ) Cytotoxic drug ( i.e. , cyclophosphamide , vinblastine , chlorambucil , methotrexate , podophylllin , camptothecin ) 13 . Subjects undergoing treatment receive treatment follow within 2 month ( 56 day ) Visit 1/Day 1 ( Baseline ) within 2 cm select treatment area plan anytime study . 5Fluorouracil ( 5FU ) Imiquimod Diclofenac Photodynamic therapy ( red blue light ) use combination photosensitize cream ( 5aminolaevulinic acid , methyl 5aminolaevulianate ) 14 . Use Ingenol Mebutate gel within 2 month ( 56 day ) Visit 1/Day 1 . Previous use ( &gt; 2 month ( 56 day ) Ingenol Mebutate gel allow different treatment area successfully treat . ) 15 . History unresponsiveness , hypersensitivity allergy ingenol mebutate therapy and/or ingredient study medication . 16 . Subjects use PUVA ( psoralen plus ultraviolet A therapy ) , UVB therapy treatment area within 6 month ( 180 day ) prior Visit 1/Day 1 ( Baseline ) plan receive treatment PUVA therapy , UVB therapy , nonprescription UV light source anywhere body study . 17 . Subjects take systemic chemotherapy medication within 6 month ( 180 day ) prior Visit 1/Day 1 ( Baseline ) plan use anytime study . 18 . Subjects undergone Botox procedure select treatment area 6 month ( 180 Days ) prior Visit 1/Day 1 ( Baseline ) . 19 . Subjects treat within 1 month ( 30 day ) plan receive treatment 1 ) systemic retinoids ( i.e. , oral isotretinoin , acitretin , bexarotene ) , 2 ) hyaluronic acid , 3 ) medicate Actinic Keratosis therapy ( i.e. , prescription topical retinoids , topical salicyclic acid , bichloroacettic acid , trichloroacetic aid , CO2 laser vaporization , electrocautery ) , 4 ) topical steroid ( use within 2 cm select treatment area study Day 15 per PI discretion allow ) anywhere treatment area study . 20 . Subjects significant change use consumer product within 30 day Visit 1/Day 1 ( Baseline ) plan use change throughout study . ( `` Significant change '' determine Principal Investigator ) 21 . Start change dose hormonal treatment ( oral , implanted , topical contraceptive androgen ) within past 3 month ( 90 day ) plan start change throughout study . Use therapy must remain constant study . 22 . Subject consumes excessive alcohol , abuse drug , condition could compromise subject 's ability comply study requirement . 23 . Participation clinical study involve investigational product , agent device ( might influence intended effect mask side effect study medication ) 30 day prior Visit 1/Day 1 ( Baseline ) throughout study . 24 . Previous enrollment study current enrollment study another participate site . 25 . Employee ( employee 's family member ) research center private practice , subject conflict interest . 26 . Subjects opinion investigator , unlikely able follow restriction protocol complete study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>